Status: Not Enrolling
ClinicalTrials.gov Identifier: NCT02745119
Genentech CHROMA: A Phase III, Multicenter, Randomized, Double-masked, Sham-controlled Study to assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
Condition: Geographic Atrophy secondary to AMD
Study Type: Interventional
Duration: 2 years
Eligibility:
For additional information, please click here
Back to Clinical Research